Parkinson's Parkinson's Research and Pathophysiology 2 — Questions and Answers
Question 1: Which biomarker test has been validated for diagnosing Parkinson's disease by detecting alpha-synuclein in skin biopsies?
- Skin biopsy alpha-synuclein seed amplification assay (SAA) (Correct answer)
- Cerebrospinal fluid tau only
- Blood LRRK2 activity assay
- Urine dopamine metabolites
Correct answer: Skin biopsy alpha-synuclein seed amplification assay (SAA)
Skin biopsy alpha-synuclein seed amplification assay (SAA) has been validated as a highly sensitive and specific biomarker for Parkinson's disease, detecting pathological alpha-synuclein in cutaneous nerves.
Question 2: Which animal toxin model is classically used in research to induce Parkinson's-like dopaminergic neuron loss?
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (Correct answer)
- Strychnine
- Botulinum toxin
- Tetrodotoxin
Correct answer: MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
MPTP, accidentally discovered when it caused Parkinsonism in drug users, selectively destroys dopaminergic neurons in the substantia nigra and is widely used in animal Parkinson's research models.
Question 3: Which neuroprotective strategy is currently being tested in Parkinson's clinical trials targeting alpha-synuclein?
- Anti-alpha-synuclein immunotherapy (antibodies) (Correct answer)
- Stem cell replacement only
- Gene therapy targeting LRRK2 only
- Mitochondrial transplantation
Correct answer: Anti-alpha-synuclein immunotherapy (antibodies)
Multiple clinical trials are testing antibodies (passive immunotherapy) and vaccines (active immunotherapy) designed to clear pathological alpha-synuclein aggregates from the brain.
Question 4: The PPMI (Parkinson's Progression Markers Initiative) study is primarily designed to:
- Identify biomarkers to track Parkinson's progression and test disease-modifying therapies (Correct answer)
- Test surgical treatments for Parkinson's
- Study caregiver outcomes in Parkinson's
- Evaluate medication side effects only
Correct answer: Identify biomarkers to track Parkinson's progression and test disease-modifying therapies
PPMI, sponsored by the Michael J. Fox Foundation, is a landmark longitudinal study enrolling thousands of participants to discover and validate biomarkers for tracking Parkinson's progression.
Question 5: Neuroinflammation in Parkinson's disease is primarily driven by activation of which brain cells?
- Microglia (Correct answer)
- Astrocytes only
- Oligodendrocytes
- Ependymal cells
Correct answer: Microglia
Activated microglia, the brain's resident immune cells, produce inflammatory cytokines and reactive oxygen species that contribute to dopaminergic neuron death in Parkinson's disease.
Question 6: Gene therapy approaches for Parkinson's disease have targeted delivery of which gene to restore dopamine synthesis?
- Aromatic amino acid decarboxylase (AADC) (Correct answer)
- Alpha-synuclein overexpression
- LRRK2 activator gene
- Tau gene
Correct answer: Aromatic amino acid decarboxylase (AADC)
AADC gene therapy uses viral vectors to deliver the gene for aromatic amino acid decarboxylase into the striatum, enabling surviving neurons to convert levodopa to dopamine more efficiently.
Parkinson's Parkinson's Research and Pathophysiology 2
Which biomarker test has been validated for diagnosing Parkinson's disease by detecting alpha-synuclein in skin biopsies?